The frequency of rs2231142 in ABCG2 among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing.
Ola AlAzzehYoussef M RomanPublished in: Pharmacogenomics (2023)
Statins are among the most commonly prescribed medications worldwide. Rosuvastatin is a moderate- to high-intensity statin depending on the prescribed dose. Statin-associated muscle symptoms are the main side effects, contributing to low adherence to statins. The missense variant rs2231142 in ABCG2 affects the functionality of the ABCG2 transporter, altering the pharmacokinetics and pharmacodynamics of rosuvastatin. This special report aims to accentuate the importance of considering the ABCG2 genotype upon prescribing rosuvastatin in high cardiovascular disease risk subgroups, specifically Native Hawaiian and Pacific Islander populations. Based on the reported frequencies of rs2231142 in ABCG2 , it may be justifiable to initiate low-dose rosuvastatin in Samoans relative to Marshallese or Native Hawaiians. Interpopulation differences in pharmacogenetic allele frequencies underscore the need to disaggregate broad population categories to achieve health equity in treatment outcomes.
Keyphrases
- cardiovascular disease
- high intensity
- low dose
- cancer stem cells
- healthcare
- resistance training
- coronary artery disease
- public health
- type diabetes
- cardiovascular risk factors
- cardiovascular events
- mental health
- physical activity
- emergency department
- depressive symptoms
- intellectual disability
- metabolic syndrome
- climate change
- social media
- adverse drug